FI941580A - Bisyklisiä ansamysiinejä - Google Patents

Bisyklisiä ansamysiinejä Download PDF

Info

Publication number
FI941580A
FI941580A FI941580A FI941580A FI941580A FI 941580 A FI941580 A FI 941580A FI 941580 A FI941580 A FI 941580A FI 941580 A FI941580 A FI 941580A FI 941580 A FI941580 A FI 941580A
Authority
FI
Finland
Prior art keywords
ansamycins
bicyclic
bicyclic ansamycins
compounds
formuladefined
Prior art date
Application number
FI941580A
Other languages
English (en)
Swedish (sv)
Other versions
FI106028B (fi
FI941580A0 (fi
Inventor
Rodney C Schnur
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI941580A0 publication Critical patent/FI941580A0/fi
Publication of FI941580A publication Critical patent/FI941580A/fi
Application granted granted Critical
Publication of FI106028B publication Critical patent/FI106028B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FI941580A 1993-04-07 1994-04-06 Menetelmä terapeuttisesti käyttökelpoisten bisyklisten geldanamysiinjohdannaisten valmistamiseksi FI106028B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/044,521 US5387584A (en) 1993-04-07 1993-04-07 Bicyclic ansamycins
US4452193 1993-04-07

Publications (3)

Publication Number Publication Date
FI941580A0 FI941580A0 (fi) 1994-04-06
FI941580A true FI941580A (fi) 1994-10-08
FI106028B FI106028B (fi) 2000-11-15

Family

ID=21932854

Family Applications (1)

Application Number Title Priority Date Filing Date
FI941580A FI106028B (fi) 1993-04-07 1994-04-06 Menetelmä terapeuttisesti käyttökelpoisten bisyklisten geldanamysiinjohdannaisten valmistamiseksi

Country Status (10)

Country Link
US (1) US5387584A (fi)
EP (1) EP0693073B1 (fi)
JP (1) JP2722280B2 (fi)
AT (1) ATE166877T1 (fi)
CA (1) CA2160137C (fi)
DE (1) DE69410790T2 (fi)
DK (1) DK0693073T3 (fi)
ES (1) ES2116594T3 (fi)
FI (1) FI106028B (fi)
WO (1) WO1994022867A1 (fi)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852496B1 (en) * 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
CA2338000C (en) 1998-07-17 2009-12-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-soluble 4-thio-maleimido derivatives and methods for their production
US6747055B1 (en) 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
MXPA01005641A (es) * 1998-12-07 2003-07-14 Ecosmart Technologies Inc Metodo y composicion para el tratamiento de cancer usando aceites vegetales esenciales naturales.
KR20030046397A (ko) * 2000-07-28 2003-06-12 슬로안-케테링인스티튜트퍼캔서리서치 세포증식성 질환 및 바이러스 감염의 치료 방법
AU2002228772B2 (en) 2000-11-02 2005-12-08 Sloan Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors
CA2426952C (en) * 2000-11-02 2012-06-26 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
AU2002252179A1 (en) * 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
US7825094B2 (en) * 2001-05-23 2010-11-02 Sloan-Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated HER 2 levels
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
EP1923061A1 (en) 2001-09-24 2008-05-21 Conforma Therapeutic Corporation Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins
JP2005504086A (ja) * 2001-09-24 2005-02-10 コンフォーマ セラピューティクス コーポレーション １７−アリルアミノゲルダナマイシン（１７−ａａｇ）および他のアンサマイシン類を製造する方法
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
AU2003217393B8 (en) * 2002-02-08 2009-06-25 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
CA2481683A1 (en) * 2002-04-10 2003-10-23 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
WO2005009345A2 (en) * 2003-06-13 2005-02-03 Kosan Biosciences, Inc. 2-desmethyl ansamycin compounds
CN100404029C (zh) * 2003-09-25 2008-07-23 中国医学科学院医药生物技术研究所 格尔德霉素（c-3559）在制备疱疹病毒生殖道感染药物中的应用
CA2545457A1 (en) 2003-11-12 2005-06-23 Kosan Biosciences, Inc. 11-o-methylgeldanamycin compounds
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
AU2004309395C1 (en) * 2003-12-23 2012-10-04 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
WO2005072766A2 (en) * 2004-01-27 2005-08-11 Boys Town National Research Hospital Peptides that bind to hsp90 proteins
WO2006034147A2 (en) * 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
CA2602257A1 (en) 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
WO2006110473A2 (en) * 2005-04-07 2006-10-19 Conforma Therapeutics Corporation Phospholipid-based pharmaceutical formulations and methods for producing and using same
AU2006242446A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
US7691392B2 (en) * 2005-04-29 2010-04-06 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either
US20080032719A1 (en) * 2005-10-01 2008-02-07 Outland Research, Llc Centralized establishment-based tracking and messaging service
EP1906950A4 (en) * 2005-06-21 2008-09-24 Infinity Discovery Inc ANSAMYCIN FORMULATIONS AND METHODS OF USE
WO2008020815A1 (en) 2006-08-15 2008-02-21 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
US20070105874A1 (en) * 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
EP1954265A2 (en) * 2005-12-01 2008-08-13 Conforma Therapeutics Corporation Compositions containing ansamycin
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP2121957A4 (en) * 2007-01-26 2010-11-10 Kosan Biosciences Inc MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
MX2009010667A (es) * 2007-04-12 2010-02-24 Joyant Pharmaceuticals Inc Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer.
CA2684211A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
JP2011501731A (ja) * 2007-09-10 2011-01-13 ユニバーシティ オブ マサチューセッツ ミトコンドリア標的化抗腫瘍剤
WO2009086170A1 (en) * 2007-12-21 2009-07-09 Joyant Pharmaceuticals, Inc. Diazonamide analogs with improved solubility
PT2254586E (pt) 2008-02-22 2015-05-18 Agency Science Tech & Res Partículas de células estaminais mesenquimais
EP2271747B1 (en) 2008-03-17 2016-09-07 Agency for Science, Technology And Research Microcarriers for pluripotent stem cell culture
JP5123429B2 (ja) * 2008-04-29 2013-01-23 ジョイアント ファーマスーティカルズ、インク． インドリン抗癌剤
US8153619B2 (en) * 2008-05-22 2012-04-10 Joyant Pharmaceuticals, Inc. Diazonamide analogs
JP5583680B2 (ja) 2008-10-15 2014-09-03 インフィニティー ファーマスーティカルズ インコーポレイテッド アンサマイシンヒドロキノン組成物
EP2471918A4 (en) 2009-09-29 2013-06-05 Takeda Pharmaceutical SCREENING PROCESS
US8551955B2 (en) 2009-10-28 2013-10-08 Joyant Pharmaceuticals, Inc. Dimeric Smac mimetics
US20120219632A1 (en) 2009-11-02 2012-08-30 Agency For Science, Technology And Research Methods for monitoring cellular states and for immortalizing mesenchymal stem cell
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
ES2652444T3 (es) 2011-04-22 2018-02-02 Joyant Pharmaceuticals, Inc. Análogos de diazonamida
EP3795694A3 (en) 2012-10-02 2021-06-23 The General Hospital Corporation d/b/a Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
CA2938626A1 (en) 2013-07-26 2015-01-29 John Rothman Compositions to improve the therapeutic benefit of bisantrene
WO2015140005A1 (en) 2014-03-19 2015-09-24 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Method of generation of pluripotent cells
US20190231694A1 (en) 2016-10-12 2019-08-01 Agency For Science, Technology And Research Method for lyophilising an exosome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987035A (en) * 1974-04-05 1976-10-19 University Of Illinois Foundation Biologically active compounds
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug

Also Published As

Publication number Publication date
US5387584A (en) 1995-02-07
JP2722280B2 (ja) 1998-03-04
JPH08503960A (ja) 1996-04-30
EP0693073A1 (en) 1996-01-24
DE69410790T2 (de) 1998-10-01
CA2160137C (en) 1999-02-09
FI106028B (fi) 2000-11-15
DK0693073T3 (da) 1998-10-12
WO1994022867A1 (en) 1994-10-13
ES2116594T3 (es) 1998-07-16
CA2160137A1 (en) 1994-10-13
DE69410790D1 (de) 1998-07-09
FI941580A0 (fi) 1994-04-06
EP0693073B1 (en) 1998-06-03
ATE166877T1 (de) 1998-06-15

Similar Documents

Publication Publication Date Title
FI941580A (fi) Bisyklisiä ansamysiinejä
DK0873340T3 (da) Heterocyklisk substituerede cyclopentanforbindelser
DK0705100T3 (da) Terapeutiske substituerede guanidiner
ATE243694T1 (de) 4-mercaptoacetylamino-(2)benzazepinon(3)- derivate, und verwendung als enkephalinase- inhibitoren
DE69620161D1 (de) Thrombininhibitoren
DE69528528D1 (de) Thrombin-inhibitoren
NO20001940L (no) Bicykliske kinase-inhibitorer
DE69430611D1 (de) Phosphonooxymethyl oder Methylthiomethylether von Taxanderivaten als Antitumormittel
TR199800773T2 (xx) Trombin inhibit�rleri.
TW225534B (fi)
TR199800854T2 (xx) Antis�tma kinolin t�revleri.
HU9500559D0 (en) New mercapto-acetamide tricyclic derivatives as enkephalinase-inhibitors
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
ZA945246B (en) Novel 9-N-Bicyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines
TR200000005T2 (tr) Sıtmaya karşı ß-alkoksiakrilatlar.
NO20002191L (no) Dofetilid polymorfer

Legal Events

Date Code Title Description
MA Patent expired